ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative148.1 M121.8 M124.8 M106.8 M103 M456.4 MRicerca e sviluppo——————Reddito operativo-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-872.6 MProventi non operativi, Totale2.5 M-5.6 M-17.1 M2.5 M1.1 M-19.1 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari-3.7 M-5.6 M-19.9 M-2.6 M1.1 M-27 MEntrate/uscite straordinarie6.2 M02.8 M5.1 M07.9 MUtile al lordo delle imposte-74.9 M-548 M-370.7 M-28.7 M-35.6 M-983 MQuota di utile——————Imposte-1 M14.9 M4.2 M-12.8 M-3.1 M3.2 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte-4.6 M-300 K-2 M100 K-2.3 M-4.5 MUtile netto al lordo delle attività cessate-73.9 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MAttività cessate12.7 M00000Utile netto-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MUtile base per azione (EPS base)-0.68-6.25-4.14-0.17-0.25-10.81Utile diluito per azione (EPS diluito)-0.68-6.25-4.14-0.17-0.25-10.81Numero medio di azioni ordinarie in circolazione89.5 M—————Azioni diluite in circolazione89.5 M—————EBITDA-34.8 M-500.6 M-310.7 M11 M5.7 M-794.6 MEBIT-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-872.6 MCosto del fatturato556.1 M534.8 M576.8 M578.6 M529.4 M2.22 BAltri costi del venduto556.1 M534.8 M576.8 M578.6 M529.4 M2.22 BAmmortamento e svalutazione (liquidità)20.8 M19.5 M19.6 M19.6 M19.3 M78 M
Fortrea Holdings Inc
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.